Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options

Poly (ADP-ribose) polymerase inhibitor (PARPi)-based combination therapies are demonstrating efficacy in patients, however, identifying the right combination for the right patient remains a critical challenge. Thus, it is urgent to develop approaches able to identify patients likely to benefit from...

Descripción completa

Detalles Bibliográficos
Autores principales: Labrie, Marilyne, Kim, Tae-Beom, Ju, Zhenlin, Lee, Sanghoon, Zhao, Wei, Fang, Yong, Lu, Yiling, Chen, Ken, Ramirez, Pedro, Frumovitz, Michael, Meyer, Larissa, Fleming, Nicole D., Sood, Anil K., Coleman, Robert L., Mills, Gordon B., Westin, Shannon N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6544405/
https://www.ncbi.nlm.nih.gov/pubmed/31191824
http://dx.doi.org/10.18632/oncotarget.26947

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6544405/
https://www.ncbi.nlm.nih.gov/pubmed/31191824
http://dx.doi.org/10.18632/oncotarget.26947

Ejemplares similares